Narmadesh Brass Industries IPO Opens Today; Price Set at ₹515 Per Share
By Shishta Dutta | Published at: Jan 12, 2026 06:04 PM IST

Mumbai, 12 January 2026: The fixed price ₹44.87 crores IPO of Narmadesh Brass Industries opened today, 12 January 2026, for subscription. The IPO will remain open until 15 January 2026. The IPO comprises a combination of fresh issue of 0.07 crore shares and an offer for sale of 0.02 crore shares
Narmadesh Brass Industries Ltd is a brass Manufacturer based in Jamnagar, Gujarat, India. The company produces Brass billets, rods, valves, including ball valves, and NRVs, plumbing & ͏sanitary fittings, agricultural sprayer parts and garden fittings, and also offers custom-made components through casting, forging, turning, CNC and VMC machining for both domestic and export markets.
Price Per Share Fixed at ₹515; Lot Size 24 Shares
Narmadesh Brass Industries IPO is a fixed price issue of ₹44.87 crores. The issue is a combination of fresh issue of 0.07 crore shares aggregating to ₹36.09 crores and offer for sale of 0.02 crore shares aggregating to ₹8.78 crores.
The IPO opens for subscription today, January 12, 2026, and closes on January 15, 2026. The allotment for the Narmadesh Brass Industries IPO is expected to be finalized on January 16, 2026. The IPO will list on BSE SME with a tentative listing date fixed as January 20, 2026.
Narmadesh Brass Industries IPO price is set at ₹515 per share. The lot size for an application is 240. The minimum amount of investment required by an individual investor (retail) is ₹2,47,200 (480 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (720 shares), amounting to ₹3,70,800.
Aryaman Financial Services Ltd. is the book-running lead manager, and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is JSK Securities & Services Pvt. Ltd.
Narmadesh Brass Industries Utilisation of Proceeds
The company proposes to utilise the net proceeds from the issue towards repayment/ prepayment, in full or in part, of certain outstanding borrowings (₹14.50 crore), purchase of machinery and equipment (₹3.29 crore), funding working capital requirements (₹10.20 crore), and meet general corporate expenses (₹4.60 crore).
Narmadesh Brass Industries Key Financials
As of 30 September 2025, the company’s assets stood at ₹63.10 crore, as compared to ₹59.66 crore as on 31 March 2025 and ₹46.68 crore on 31 March 2024. Total income stood at ₹34.21 crore as against ₹88.05 crore in the previous year. Profit after tax (PAT) decreased to ₹4.01 crore from ₹5.72 crore in March 2025 and ₹7.10 crore in March 2024. EBITDA was at ₹6.24 crore, and net worth surged to ₹22.46 crore. Borrowings reduced to ₹19.21 crore from ₹24.73 crore.
Day 1 Subscription at 0.24 Times So Far
By January 12, 2026, 1:15:01 PM (Day 1), Narmadesh Brass Industries IPO subscribed 0.24 times. The public issue subscribed 0.03 times in the individual investors category, 0.46 times in the NII category, and QIBs did not subscribe so far.
I͏n t͏he non-institutional category, ͏4,12,800 shares were offered, and bids were received for 1͏,88 ,͏400 ͏sha͏res. In the individual investo͏r category 4,͏12,800 shares ͏w͏er͏e offered, but bids ͏were ͏placed for only 10,560 shares. Overall, the issue offered a total͏ o͏f͏ 8,͏2͏5,600 shares and received ͏bids ͏for 1,98,͏960 shares acr͏oss all ͏categories.
References
- https://www.bseindia.com/markets/publicIssues/DisplayIPO.aspx?id=4402&type=FPO&idtype=1&status=L&IPONo=7544&startdt=12/Jan/2026
- https://nsearchives.nseindia.com/emerge/corporates/content/NarmadeshBrassIndustriesLimited_DP.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations

